Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of “Buy” from Analysts
Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has received a consensus recommendation of “Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have issued ratings on the stock […]
Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has received a consensus recommendation of “Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have issued ratings on the stock […]
